Navigation Links
Solta Medical to Present at the JMP Securities Research Conference
Date:5/2/2011

HAYWARD, Calif., May 2, 2011 /PRNewswire/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced that it will present at the Tenth Annual JMP Securities Research Conference at the Ritz-Carlton in San Francisco on Monday, May 9, 2011 at 1:00 pm Pacific Time. Stephen J. Fanning, Chairman, President and Chief Executive Officer, will review the company's business strategy and recent corporate events.

Attendance at this conference is by invitation only. Solta will offer a live audio webcast of its presentation which may be accessed at the Investor Relations section of the Company's website at www.solta.com. An archived replay of the presentation will be available for 15 days, also at www.solta.com.

About Solta Medical, Inc.

Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's four premier brands: Thermage®, Fraxel®, Isolaz®, and CLARO®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the first laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the first FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. Since 2002, over one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.


'/>"/>
SOURCE Solta Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solta Medical Announces First Quarter 2011 Results Release and Conference Call
2. Solta Medical Reports Fourth Quarter and Full Year 2010 Results
3. Solta Medical Announces Full Year and Fourth Quarter 2010 Results Release and Conference Call
4. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
5. Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices
6. Solta Medical Reports Third Quarter 2010 Results
7. Solta Medical Announces FDA 510(k) Clearance of Fraxel re:store Dual Laser System for the Treatment of Actinic Keratosis
8. Len DeBenedictis Retires as Chief Technology Officer of Solta Medical, Inc.
9. Solta Medical, Inc. Announces Second Quarter 2010 Results Release Date and Conference Call
10. Solta Medical Announces Thermage CPT™ and Fraxel re:store® Dual Systems Receive Health Canada Approval
11. Solta Medical Receives Provectus Innovation Award at MDB Capital Groups Bright Lights Intellectual Property Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... York City-based market research firm Kalorama Information notes seven trends ... new products to new costs, to the threat of generic ... Potential Pipeline Disruptors . Among them are ... Age-Driven Growth - True Impact Moment Arriving   ... growing population and, to a more extreme extent, the aging ...
(Date:7/11/2017)... , July 11, 2017  Bayer has awarded grants ... countries as part of its prestigious Bayer Hemophilia Awards Program ... of Philadelphia and Uniformed Services University ... are among the winners. Grant recipients were announced last night ... Hemostasis (ISTH) 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
Breaking Medicine Technology:
(Date:7/24/2017)... PHILADELPHIA (PRWEB) , ... July 24, 2017 , ... ... Health , two organizations that already work hand-in-hand on an Innovation Collaboration program, ... transform the access, quality, experience and cost of the care members and patients ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... (adipose) transfer systems announces the issuance of United States Patent Number 9,695,398 (the ... adipose filtration technology. The '398 and '324 patents cover methods and systems ...
(Date:7/24/2017)... ... 24, 2017 , ... The 2017 NCSL International Workshop & ... focuses on the new ISO/IEC 17025 standards. This marks the first time in ... calibration will be changed. , As an exhibitor, METTLER TOLEDO will showcase ...
(Date:7/24/2017)... ... July 24, 2017 , ... A ... focused on delivering end-to-end sleep health care at scale, indicates record-breaking adherence ... that adherence rates for positive airway pressure (PAP) therapy, the most widely utilized ...
(Date:7/24/2017)... Calif. (PRWEB) , ... July 24, 2017 , ... A ... from food addiction to sexual abuse, and how she has overcome them. “Forbidden Memories: ... instances in her life and how she has risen above. , In “Memories,” readers ...
Breaking Medicine News(10 mins):